Mufg Securitiesは、強い決算と見通しの引き上げを受けて、Quest Diagnosticsの持分を増強しました。 Mufg Securities boosted its Quest Diagnostics stake after strong earnings and raised guidance.

Mufg Securities Americas Inc.は,Q2で Quest Diagnostics (DGX) の株式を25.9%増額し,現在,約444,000ドルの価値の2,474株を所有しています. Mufg Securities Americas Inc. boosted its stake in Quest Diagnostics (DGX) by 25.9% in Q2, now holding 2,474 shares worth about $444,000. 同社は10月21日に第3四半期に強な業績を報告し,推定値より2.60ドルEPS0.09ドルと,同年比13.2%の売上高で282億ドルを記録した. The company reported strong Q3 results on October 21, with $2.60 EPS—$0.09 above estimates—and $2.82 billion in revenue, up 13.2% year-over-year. クエスト・ダイアグノスティクスは2025年全年EPSの予測値を9.76ドル9.84ドルに上げ,四半期配当を0.80ドルで1.7%の利回りで発表しました. Quest Diagnostics raised its 2025 full-year EPS guidance to $9.76–$9.84 and announced a quarterly dividend of $0.80, yielding 1.7%. 株式の市場キャピタルは2118億ドル,P/Eは22.35で,目標値196.31ドルの適度な買いコンセンサスがあります. The stock has a market cap of $21.18 billion, a P/E of 22.35, and a moderate buy consensus with a $196.31 target. 内部関係者は38,118株を売り,ホライゾン・キネティクスは450株の株式を売却した. Insiders sold 38,118 shares in the quarter, while Horizon Kinetics reduced its stake by 450 shares.